**Press Release**
30 September 2025 11:00:00 CEST

# Affibody Announces Broad Scientific Progress at EANM 2025

**Solna, Sweden, September 30, 2025. Affibody AB ("Affibody") today announced it will have substantial scientific presence at the 2025 Congress of the European Association of Nuclear Medicine (EANM), taking place October 4-8 in Barcelona. The company will be represented with five presentations covering key aspects of radiopharmaceutical development, underscoring Affibody's diverse capabilities in the field.**

Affibodys innovative radiopharmaceutical pipeline will be featured in presentations covering:
•the successful development of a cGMP-compliant manufacturing process for Affibody's HER2-targeting radiotherapeutic candidate ABY-271 currently in a First-In-Human study;
•clinical data on the PET imaging candidate tezatabep matraxetan (ABY-025) demonstrating highly specific visualization of HER2-positive lesions throughout the body in patients with metastatic breast cancer;
•preclinical data on PET imaging of B7-H3 expression using Gallium-68-labelled Affibody® molecules showing high tumor-specific uptake; and
•favorable preclinical biodistribution of a HER2-targeting Affibody® molecule labeled with the novel radionuclide Terbium-161.

"We are delighted to have so many abstracts accepted at EANM 2025, a world-leading scientific event in nuclear medicine," said David Bejker, Chief Executive Officer of Affibody. "This recognition underscores our position at the forefront of radiopharmaceutical development and reflects our dedication to turning scientific innovation into meaningful improvements for patients. We are grateful for the opportunity to collaborate with leading experts in the field, whose contributions are instrumental to our progress."

**Abstract presentations**
Title: Preclinical PET Imaging of B7-H3 Expression Using Affibody Molecules Labelled with Positron-Emitting Gallium-68
Presenter: Prof. Fredrik Frejd, CSO Affibody
Date and Time: October 6, 2025, 8:00 - 9:30 CEST
Session: Technologists' Track Oral Presentations 2 - Technologists Committee: Advanced Practice and Novel Solutions
Format: Oral
Presentation ID: OP-320

Title: Head-to-head comparison of ABD-fused Affibody Molecule labelled with Lu-177 and Tb-161
Presenter: Prof. Vladimir Tolmachev, Uppsala University
Date and Time: October 8, 2025, 8:00 - 9:30 CEST
Session: M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: Antibodies and Co.
Format: Oral
Presentation ID: OP-764

Title: Development of a cGMP-compliant automated synthesis of the radiotherapeutic [177Lu]Lu-ABY-271: Enabling reliable radiolabelling for a first-in-human phase I study
Presenter: Samar Omer, Department of Oncology-Pathology, Translational Theranostics Group, Karolinska Institutet
Date and Time: October 6, 2025, 15:00 - 16:30 CEST
Session: e-Poster Presentations Session 7 - Radiopharmaceutical Sciences Committee: Radiopharmacy e-Poster Presentations Session Radiochemistry and Quality Control
Format: Oral e-Poster
Presentation ID: EPS-154

Title: Visualising HER2 Heterogeneity in Advanced Breast Cancer using [68Ga]Ga-ABY-025 PET - a Single Centre Polish Experience
Presenter: Prof. Gabriela Kramer-Marek, The Institute of Cancer Research, London and Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice
Session: e-Poster Area, B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast
Format: e-Poster
Presentation ID: EP-0207

Title: Diagnostic Contribution of [68Ga]Ga-ABY-025 PET in HER2-Positive Breast Cancer: Beyond [18F] FDG PET
Presenter: Dr Ali Alhuseinalkhudhur, Department of Immunology, Genetics and Pathology, Uppsala University and Department of Surgical Sciences, Molecular imaging and medical physics, Uppsala University
Session: e-Poster Area, B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others)
Format: e-Poster
Presentation ID: EP-0289

View the EANM abstracts here: https://eanm25.eanm.org/abstracts-book/

**About metastatic breast cancer**

Metastatic breast cancer is cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain. It has poor prognosis and cannot usually be treated curatively with surgery or systemic therapies. Instead, the aim of treatment shifts to slow the cancer growth, manage symptoms, and improve quality of life. Approximately 6-10% of women are diagnosed with metastatic breast cancer at their initial diagnosis. However, nearly 30 percent of women diagnosed with early-stage breast cancer will see their disease metastasize and spread to other organs over time.

**About tezatabep matraxetan**

Tezatabep matraxetan (ABY-025) is a Gallium-68-labeled PET tracer candidate that aims to enable non-invasive visualization of HER2 expression in cancer patients. The high affinity and rapid clearance of tezatabep matraxetan from blood and normal organs allows HER2 assessment within hours.

**About HER2**

HER2 is a protein that is involved in cell growth. HER2 is overexpressed by some types of cancer cells, including breast, stomach, esophageal, ovarian, bladder, and pancreatic cancers. HER2 may cause cancer cells to grow more quickly and spread to other parts of the body and HER2-positive cancers are therefore considered more aggressive than HER2-negative cancers. However, they are much more likely to respond to treatments that target the HER2 protein. HER2-targeted therapies can remain effective even after multiple lines of treatment.

**About ABY-271**

ABY-271 is a radiotherapeutic candidate aimed at tumor cells that express HER2, regardless of their position in the body. The project builds on previous clinical research insights from the development of tezatabep matraxetan (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 with the radioisotope lutetium-177 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells upon binding.

**About B7-H3**

B7-H3 (also known as CD276) is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.

**About Affibody® molecules**

Affibody® molecules are a novel drug class of small therapeutic proteins with characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. The Company has created a large library consisting of more than ten billion Affibody® molecules, all with unique binding sites, from which binders to given targets are selected. Affibody® molecules are only 6 kDa in size.

They have demonstrated clinical utilities both as tumor-targeting moieties through their small size and as efficacious disease blocking agents in autoimmune indications by utilizing the inherent properties that allow multi-specific formats.

## About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

## Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

## Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

## Contacts (Media)

Richard Hayhurst, 59° North Communications, richard.hayhurst@59north.bio, +44 (0) 7711 8215727

## Attachments

Affibody Announces Broad Scientific Progress at EANM 2025